Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VNN2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VNN2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View VNN2 Products |
| Gene Delivery | VNN2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View VNN2 Products |
| Benchmark Ab | Anti-VNN2 Recombinant Antibody Recombinant positive control. |
View VNN2 Products |
| Validator | VNN2 siRNA Set For knockdown verification. |
View VNN2 Products |
| Related Target A | VNN1 High sequence homology; essential for off-target and selectivity screening. |
View VNN1 Products |
| Related Target B | CXCR2 Synergistic pathway in neutrophil-driven inflammatory diseases and tumor microenvironment modulation. |
View CXCR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| VNN1 vs VNN2 Subfamily Counter Screening | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Native Glycosylation & Conformation of GPI-anchored protein | HEK293-expressed recombinant ECD-Fc fusion to preserve native post-translational modifications. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) sequence-verified and included. |
| False Positives in Binding Assays | Validated siRNA sets included for target knockdown and specificity verification. |
Live VNN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The exploration of VNN2 (Vanin-2/GPI-80) therapeutics is gaining traction, with major players shifting focus from traditional neutrophil biology to oncology and inflammatory disease modulation. As first-generation targeting strategies reach preclinical and early clinical evaluation, the next wave of R&D is targeting the selective inhibition of VNN2 over its highly homologous family member VNN1 to avoid systemic metabolic toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biotech Startups | Inflammatory Bowel Disease (IBD), PNH | Adhesion & Migration Blockade (Need native-conformation ECD) |
| Antibody-Drug Conjugates (ADCs) | Oncology-focused Biopharma | Acute Myeloid Leukemia (AML), Solid Tumors | Internalization Assay (Need high-purity ECD-Fc) |
| Small Molecule Inhibitors | Inhibitor Screening Consortia | Neutrophil-mediated Inflammatory Disorders | Selectivity Assay (Need VNN1 vs VNN2 Mutant Panels) |